SEC Tracker
Get the app

Plus Therapeutics CNSY

Plus Therapeutics Q1 FY24: revenue $1.7M; diluted EPS −$18.75

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Plus Therapeutics reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$1.7MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$3.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$18.75No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$0.7510-Q income statement, on EDGAR
  4. Cash and cash equivalents$2.9MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$4.5MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Plus Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (3841) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Femasys FEMY public float $30M, Jun 30, 2025
  2. DarioHealth DRIO public float $28M, Jun 30, 2025
  3. HeartBeam BEAT public float $36M, Jun 30, 2025
  4. Nephros NEPH public float $27M, Jun 30, 2025
  5. RenovoRx RNXT public float $27M, Jun 30, 2025